N	tients with Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes 
1	odophyllotoxin-related acute myeloid leukemia appears to evolve within 3 ye
2	 leukemia (ALL) and 38 acute myeloid leukemia (AML) using the       monoclo
3	roteases inhibitors in acute myeloid leukemia at the  onset of the disease 
4	pient in remission  of acute myeloid leukemia and receiving cyclosporin A. 
5	learn more about adult acute myeloid leukemia, call the National Cancer  In
6	apoptosis of the human acute myeloid leukemia HL-60 cells. In a previous re
7	ysplastic syndrome and acute myeloid leukemia following melphalan and cyclo
8	 Incidences of 2-8% in acute myeloid leukemia have been reported in various
9	tted  No B-cell ALL or acute myeloid leukemia  Concurrent registration on p
10	elapsed or progressive acute myeloid leukemia (AML) is poor.  The selection
11	iant in a patient with acute myeloid leukemia detected by a new asymmetric 
12	               De novo acute myeloid leukemia (AML) that has failed inducti
13	hoblastic leukemia and acute myeloid leukemia. Currently,       specific ge
14	ow transplantation for acute myeloid leukemia do not appear to confer      
15	  De novo or secondary acute myeloid leukemia of any morphologic type    Ac
16	tients with Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes